EUVIMEDEUVIMED entdecken
Open Access

Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis

Aiko Oka, Aiko I Klingler, Masanori Kidoguchi, Julie A Poposki, Lydia A Suh, Junqin Bai, Whitney W Stevens, Anju T Peters, Leslie C Grammer, Kevin C Welch, Stephanie S Smith, David B Conley und 6 weitere

Journal of Allergy and Clinical Immunology · 2025-08 · 156 (2) · 463-467.e2

DOI: 10.1016/j.jaci.2025.02.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-08. Verfasst von Aiko Oka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Otolaryn…. Hauptthemen laut MEDLINE: Cytokines, Sinusitis, Rhinitis, Nasal Polyps. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, AstraZeneca PLC, NIH NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thymic stromal lymphopoietin (TSLP) and its functional cleavage products are elevated in nasal polyps (NPs) and play important roles in type 2 (T2) inflammation in chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) by activating myeloid dendritic cells (mDCs) and group 2 innate lymphoid cells (ILC2s). However, whether tezepelumab, a human mAb against TSLP, inhibits functional cleaved TSLP and also the role of TSLP in CRS without nasal polyps (CRSsNP) have not yet been studied. OBJECTIVE: We sought to investigate the effects of tezepelumab on cleaved TSLP in CRS. METHODS: The mRNA expression levels for TSLP and T2 markers in ethmoid tissues (ETs) from 31 controls and 118 patients with CRSsNP and in NPs from 53 patients with CRSwNP were measured by quantitative RT-PCR. Cleaved TSLP was prepared from full-length recombinant TSLP by incubation with tissue extracts of NPs and CRSsNP ETs. The effects of tezepelumab on cleaved TSLP-induced inflammation were evaluated using PBMCs by monitoring the production of chemokines (CCL17 and CCL22 for mDCs) and cytokines (IL-5 and IL-13 for ILC2s). RESULTS: The mRNA expression level of TSLP was elevated not only in NPs but also in ETs from T2 CRSsNP compared with non-T2 CRSsNP and controls, and was positively correlated with T2 markers in CRSsNP (P < .001). CRSsNP ET also truncated and created highly active TSLP products. The activation of mDCs and ILC2s by full-length TSLP and cleaved TSLP created by ET and NP extracts was dose-dependently inhibited by tezepelumab. CONCLUSIONS: TSLP plays a role in T2 inflammation in CRSsNP and CRSwNP. Treatment with tezepelumab may benefit patients with T2 CRS by inhibiting active forms of TSLP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesSinusitisRhinitisNasal PolypsAntibodies, Monoclonal, HumanizedHumansThymic Stromal LymphopoietinChronic DiseaseMaleFemaleAdultMiddle AgedChemokine CCL17AgedRhinosinusitis

Stichwörter der Autor:innen

CRSsNPCRSwNPT2 inflammationTSLPTezepelumabchronic rhinosinusitisnasal polypsposttranslational modification

Substanzen

Thymic Stromal LymphopoietinCytokinestezepelumabAntibodies, Monoclonal, HumanizedChemokine CCL17TSLP protein, humanCCL17 protein, human

Autor:innen und Institutionen

  • Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Otolaryngology, International University of Health and Welfare, Narita, Chiba,…
  • Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
  • Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Division of Otorhinolaryngology and Head & Neck Surgery, Department of Sensory and Locomotor…
  • Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill.
  • Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago,…
  • Division of Otorhinolaryngology and Head & Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Science, University of Fukui, Yoshida-gun, Fukui, Japan.

Förderung

  • NIAID NIH HHS
  • AstraZeneca PLC
  • NIH NIAID
  • Uehara Memorial Foundation
  • Japan Agency for Medical Research and Development

Zitieren

APA

Oka, A., Klingler, A. I., Kidoguchi, M., Poposki, J. A., Suh, L. A., Bai, J., Stevens, W. W., Peters, A. T., Grammer, L. C., Welch, K. C., Smith, S. S., Conley, D. B., Schleimer, R. P., Kern, R. C., Tan, B. K., Fujieda, S., Okano, M., & Kato, A. (2025). Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 156(2), 463-467.e2. https://doi.org/10.1016/j.jaci.2025.02.031

Vancouver

Oka A, Klingler AI, Kidoguchi M, Poposki JA, Suh LA, Bai J, et al. Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology. 2025;156(2):463-467.e2. doi:10.1016/j.jaci.2025.02.031

BibTeX
@article{Oka2025,
  author = {Oka, Aiko and Klingler, Aiko I and Kidoguchi, Masanori and Poposki, Julie A and Suh, Lydia A and Bai, Junqin and Stevens, Whitney W and Peters, Anju T and Grammer, Leslie C and Welch, Kevin C and Smith, Stephanie S and Conley, David B and Schleimer, Robert P and Kern, Robert C and Tan, Bruce K and Fujieda, Shigeharu and Okano, Mitsuhiro and Kato, Atsushi},
  title = {Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  volume = {156},
  number = {2},
  pages = {463--467.e2},
  doi = {10.1016/j.jaci.2025.02.031}
}
Kostenlos starten →